Abstract
We devised a scoring system to identify patients with systemic sclerosis (SSc) at risk for pulmonary hypertension (PH) and predict all-cause mortality. Using 7 variables obtained via pulmonary function testing, echocardiography, and computed tomographic chest imaging, we applied the score to a retrospective cohort of 117 patients with SSc. There were 60 (51.3%) who were diagnosed with PH by right heart catheterization. Using a scoring threshold ≥ 0, our decision tool predicted PH with a sensitivity, specificity, and accuracy of 0.87 (95% CI 0.75, 0.94), 0.74 (95% CI 0.60, 0.84), and 0.80 (95% CI 0.72, 0.87), respectively. When adjusted for age at PH diagnosis, sex, and receipt of pulmonary arterial vasodilators, each one-point score increase was associated with an adjusted HR of 1.19 (95% CI 1.05, 1.34) for all-cause mortality. With further validation in external cohorts, our simplified clinical decision tool may better streamline earlier detection of PH in SSc.
Funding Information
  • United Therapeutics Corporation
  • National Scleroderma Foundation
  • American Heart Association (23CDA1052352)
  • Parker B. Francis Fellowship
  • National Center for Advancing Translational Sciences (1UL1TR001430, 1UL1TR001430)
  • Doris Duke Charitable Foundation (2021261)
  • John Templeton Foundation (62288)
  • National Heart, Lung, and Blood Institute (1R01HL155955-01A1, 1UG3 HL143192-01A1)
  • VA Boston Healthcare System
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (CCCR P30 AR072571)
  • Health Resources and Services Administration (U1EMC27864‐08‐00)
  • Bayer
  • Novo Nordisk
  • Novartis

This publication has 17 references indexed in Scilit: